Treating Psychological Factors in Patients With Heart Disease: Where Have We Been, How Shall We Proceed? Authors: Matthew M Burg Published: 2026 The importance of stress and emotional factors to heart disease has been understood for millennia. Perhaps the most famous early example is that of Sir John Hunter, the 18th century scientist and surgeon who said, “My life is at the mercy of any rascal who chooses to put me in a passion”; Hunter collapsed and died after a heated argument. 1 Later in the 20th century, the cardiologists Rosenman and Friedman established behavior pattern A as an action emotion complex, characterized by time‐pressured achievement striving, and easily aroused anger and hostility, all demonstrated during a structured clinical interview. 2 Starting in the mid‐1980s, depression became a focus of behavioral medicine researchers, with 2 meta‐analyses showing that even subsyndromal levels of depressive symptoms are associated with increased risk for incident cardiac events and cardiac recurrence. 3 , 4 More recently, posttraumatic stress disorder has been added to the list of stress/emotional factors that contribute to risk of incident cardiac events. 5 This research led to the development and testing of interventions to treat the behavioral/emotional target. Rosenman and Friedman's Recurrent Cardiac Prevention Project, 2 used a weekly, small‐group, cognitive behaviorally based intervention, along with specific skills training (eg, relaxation skills, self‐examination, and talk skills). A form of this intervention was used by Orth‐Gomer and colleagues with post‐cardiac event women, showing a reduced cardiac event risk over many years, 6 and by Blumenthal and colleagues, who showed both a reduction in daily stress‐provoked (silent) ischemic events, and reduced health care use and cost. 7 The National Institutes of Health funded the ENRICHD (Enhancing Recovery in Coronary Heart Disease) randomized clinical trial, 8 which is perhaps the largest postcardiac event trial targeting depression. Gold‐standard cognitive therapy for depression was augmented with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy for severe depression and a group‐delivered stress reduction program, with treatment starting ≈1 month post‐cardiac event and lasting up to 6 months. The effect on depression was modest, and there was no effect on cardiac recurrence. A postmortem 9 suggested that many patients experienced spontaneous remission within months of their event, thus suggesting a longer wait period before depression treatment should commence. The subsequent COPES‐2 10 and CODIACS 11 trials did this with a patient preference, stepped care, brief, (often) telephone‐delivered problem‐solving therapy, along with SSRI medication for severe or unresponsive depression. Both trials showed a significant and meaningful reduction in depression. An important innovation for the COPES‐2 (Coronary Psychosocial Evaluation Studies) and CODIACS (Comparison of Depression Interventions After Acute Coronary Syndrome) trials was the use of telephone‐based treatment, which improved reach. Over the past 10 years, web‐based interventions have proliferated, further improving reach and convenience, and most recently, smartphone apps have been developed for a range of behavioral factors that are associated with cardiac events, including for stress reduction and improved sleep. Another evolution has been a shift away from cardiac recurrence and mortality to focusing on quality‐of‐life factors, in part because they can contribute to health care use and cost. A good example includes patients with atrial fibrillation, many of whom become somatically focused (eg, perceived or real increases in heart rate provoke anxiety). This, along with smartphone‐based apps that assess cardiac rhythm, can drive patients with atrial fibrillation to frequently contact their physicians and/or report to hospital emergency rooms. 12 A recent clinical trial using online cognitive behavior therapy, including exposure, for patients with atrial fibrillation showed improved atrial fibrillation‐specific quality of life and reduced health care use. 13 Which brings us to the clinical trial reported by Leissner et al 14 in the current issue of the Journal of the American Heart Association (JAHA). These investigators used a web‐based, 9‐step cognitive behavioral therapy program to reduce a composite index of stress and anxiety among patients who had been hospitalized with a suspected diagnosis of either Takatsubo cardiomyopathy or myocardial infarction with nonobstructive coronaries (MINOCA). The relatively small (n=88) trial, which required 7 emergency hospitals for recruitment, did not show a significant normalization of the composite index overall, although secondary, hypothesis‐generating analyses showed an effect for patients with Takatsubo cardiomyopathy versus MINOCA. The multiple measures of stress and emotional factors also provide for hypothesis generation and potentially better targeting (eg, on other or additional psychological factors) in future clinical trials. The trial targeted patients with a suspected diagnosis of either MINOCA or Takotsubo syndrome (TS) after hospitalization, who also demonstrated elevated symptoms of stress and/or anxiety ≈1 month later. This focus is highly novel, given that these are relatively rare clinical presentations and are underrepresented in behavioral medicine research relative to other cardiac populations (eg, cardiac event with coronary obstruction, heart failure, cardiac arrhythmia). Patients with MINOCA and TS overall have worse mental health status and quality of life after an acute event, with a prevalence comparable with what is found in other postevent cardiac populations, which can range up to 25%. 15 The combination of both patients with TS and MINOCA in a single trial is something of a double‐edged sword. As noted by the authors, these are distinct clinical presentations with different pathophysiology. TS was originally thought to be a consequence of extreme emotional events, with more recent data demonstrating this to be the case in only one‐third of patients. 16 Similarly, MINOCA can be a function of heterogenous pathophysiology in the coronary microvascular circulation. 17 Both conditions are difficult to manage, and associated with uncertainty for patients. There is no definitive treatment to avoid recurrence (approximately 6%–7%), 18 , 19 or prevent major adverse events, which can leave the patient with anxiety about the future. Furthermore, with MINOCA, anginal symptom onset is often unpredictable, and can recur frequently, and until the definitive diagnosis is made with the proper interventional and imaging techniques, the patient is left in a state of limbo and anxiety on how to understand their condition. The CORMICA (Coronary Microvascular Angina) trial 20 found that proper MINOCA diagnosis, followed by (recommended) stratified medical therapy, led to sustained angina improvement and better quality of life at 1 year. Yet, a close examination of the data raises questions as to how the medical therapy is actually received by patients, which was recommended to the patient's treating physician, not delivered by the trial. It is thus possible that receiving a definitive diagnosis alone was related to a reduction in uncertainty and distress, with resulting improvements in angina reports and quality of life. Cognitive behavioral therapy was the treatment approach selected by the research team, with the specifics of the intervention informed by input from patients with TS/MINOCA; feasibility testing (N=11, 7 with TS, 4 with MINOCA) found it helpful and relevant to patient concerns. The use of internet‐delivered content can improve reach, whereas psychologist backup can help maintain intervention integrity. With regard to use of this specific therapy approach, is important to note that cognitive behavioral therapy has become an umbrella term used to describe a range of specific therapy elements. These can include some form of relaxation/meditation, behavioral activation including physical activity, graded exposure to feared stimuli, and a process of Socratic self‐talk directed to depressogenic, stressful, and/or anxiety‐provoking thoughts and feelings. In the current study, we assume that the TS event was the first for the participating patients, whereas for participants with MINOCA, we do not know whether they had been experiencing anginal symptoms for some time before receipt of a diagnosis. There was a 56% improvement rate among patients with MINOCA assigned to usual care versus 25% for patients with TS; among those receiving the intervention, there was a 31% improvement for patients with MINOCA versus 67% for patients with TS, all contrary to the improvement rates for usual care and intervention that were used in power analyses. Receiving a diagnosis after a period with symptoms may have reduced stress and anxiety for patients with MINOCA, thus reducing the power to find an effect and indicating that a longer wait period after diagnosis may have been warranted. Furthermore, it may be that a stress/anxiety reduction intervention for the patient with TS, who had experienced a sudden and distressing initial event, was helpful, whereas for the patient with MINOCA, who finally had a definitive diagnosis and was thus somewhat relieved, the stress reduction intervention may have left their disease salient to them, thus maintaining their uncertainty about the future rather than reducing their anxiety and (dis)stress. The reason for the psychological treatment that approximately one‐third of patients had previously received, and its proximity to study participation, is also not known, and this variable was not investigated in secondary analyses. It may be that some patients continued to receive such treatment, regardless of their study group assignment. Regardless, it indicates premorbid psychological (dis)stress that may have not been addressed by the study treatment and that could have influenced the efficacy of the intervention. Together, this information suggests several things for consideration as we seek to address these mental health issues that cardiac patients experience, which define quality of life, and that are linked to morbidity/mortality and use/cost. Although the use of internet‐based intervention delivery supports reach, cost reduction, and greater patient inclusion, as tested in the current study, it may not provide for sufficient personalization (eg, the content delivered to each patient was the same regardless of how anxiety and [dis]stress was being experienced by, and the impact on quality of life for, a given patient's life). It does not allow for the personalization that may be essential for the unique, personal experiences that comprise mental health, or absence thereof. Furthermore, it does not provide for integration within the delivery of cardiologic care more broadly. A focus solely on mental health outcomes can serve to perpetuate fractured care and potentially, stigma. In many health care contexts where costs of care are high and increasing, it also does not provide a reason for addressing these patient needs. Because the outcome(s) of medical morbidity/mortality would require thousands of participants due to the relatively low 1‐year postcardiac event mortality, reduction in health care use and cost should be included as an outcome that can drive interest in the clinical domain. Thus, a more clinically integrated and pragmatic approach to clinical trials, that include outcomes of interest to a broader group of stakeholders (eg, health care system administrators and payers) is warranted. Placing the trial within the contextual health care delivery system would provide for a longer period of watchful waiting with support, as suggested by the depression trials, and should these trials prove successful, would set the stage for integration of whole person care clinically. Clinical trials using a more personalized approach for addressing psychological factors, whether depression, anxiety, or distress, after cardiac events may also be warranted. Such an approach might have better addressed the needs of the patients in this trial, where less than half completed the optional graded exposure steps that may have been most important for patients with MINOCA. More personalized interventions in future pragmatic clinical trials would also potentially create the opportunity to broaden inclusion criteria (eg, to include patients after any acute cardiac event), thereby increasing the sample size and statistical power along with the usefulness of findings to inform cardiologic care more broadly. Disclosures None. This article was sent to Ajay K. Gupta, MD, MSc, PhD, FRCP, FESC, Senior Associate Editor, for editorial decision and final disposition. See Article by Leissner et al. For Disclosures, see page 3. References